Mondego Bio

Executive Summary

Mondego Bio, headquartered in Portugal's Biocant biotech park, is a pre-clinical stage biotechnology company developing best-in-class inhibitors of Protein tyrosine phosphatase non-receptor type 2 (PTPN2) for immuno-oncology. PTPN2 is a validated target in oncology, and its inhibition is expected to enhance anti-tumor immunity by potentiating T-cell receptor and cytokine signaling. Mondego’s approach aims to improve upon existing PTPN2 inhibitors by optimizing selectivity and pharmacokinetics, potentially offering a superior safety and tolerability profile. The company was founded in 2019 and has remained largely under the radar, operating in the early drug discovery space. While no specific funding rounds have been disclosed, the company is advancing its lead program toward IND-enabling studies. The pre-clinical landscape for PTPN2 inhibitors is competitive, with several biotechs and large pharma exploring similar mechanisms, but Mondego’s focus on a differentiated molecular design may position it favorably if preclinical data confirm a best-in-class profile. The company’s progress will depend on successful completion of in vivo efficacy and safety studies, as well as securing additional financing to support clinical translation.

Upcoming Catalysts (preview)

• TBDIND-enabling studies completion and regulatory submission40% success
• TBDPresentation of preclinical efficacy data at a major oncology conference60% success
• TBDSeries A financing round to advance to Phase I50% success